Molecular biologist and entrepreneur, he has been working in the international vaccines business since 1992 (Chiron Corp), also dealing with alliances and technology transfers between biological institutes and manufacturers. Founder of Bionet Asia and Valliance, two vaccine companies with 20 years of success.

Counts on 30 years of experience in Monte dei Paschi Group: After several years in Finance and International Markets Area he became Head of Human Resources. Further more he covered the role of Head of Corporate, Head of Logistics Area and finally General Manager of MPS Credit Management.

Counts on 25 years' experience in General Management, Business Development and International Sales & Commercial Operations. Focused on Bio-Pharmaceutical, Drug Delivery and Healthcare. Executive MBA at IMD Switzerland.

Holds a degree in Pharmaceutical Chemistry and Technology and started his career with Dompé S.p.A, being part of the team who founded and expanded its research centre. Founding executive of Novartis Vaccine Institute for Global Health (NVGH) as Head of Technical Development and then, with GSK taking over Novartis vaccine business, as Head of Technical and Business Strategy of GVGH. Holds several patents and pioneered innovative technical developments in several fields including GMMA and glycoconjugate based vaccines. Quality Auditor and investigational products cGMP manufacturing expert. Registered Qualified Person (QP).

(University of Cambridge, UK and AchilleS Vaccines) joins AchilleS Vaccines as Chief Scientific Advisor. Pietro Mastroeni is a Medical Doctor; he holds a PhD and a ScD from the University of Cambridge; he is also a Fellow of the Royal Society of Biology (FRSB) and a Fellow of the American Academy of Microbiology. Pietro Mastroeni is an expert in bacterial pathogenesis and immunology, bacterial genetics and in the development and testing of vaccines including those based on OMV. Pietro Mastroeni has led pioneering and impactful fundamental research that is profoundly influencing modern vaccinology.

joins AchilleS as Chief Financial Officer and Head of Finance after 25 years in Capital Markets, Fund Management and Venture Finance. After graduating in Business from Bocconi University in Milan, he worked among others with Dresdner Bank, Chase Manhattan Bank, JP Morgan and lately with the Austrian Asset Manager C-Quadrat where he was group Head of Alternative Funds and COO of their UK entity.

Aldo Tagliabue is an immunologist who was involved in building up several R&D initiatives for vaccines and biotech drugs including the International Vaccine Institute in Seoul (ROK) and Novartis Vaccines Institute for Global Health in Siena (Italy). He was instrumental in designing several public-private partnerships funded by EU Commission.

National Institute of Molecular Genetics and CheckmAb Srl - Renata Grifantini is a molecular and cellular biologist with consolidated experience in industrial and translational research in the field of vaccines against human pathogen and preclinical development of moleculat targets and monoclonal antibodies for immunotherapy. She has led innovative research on the design of recombinant OMV as vaccine delivery system and characterization of elicited immune responses.